Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2165–2168. doi: 10.1128/aac.38.9.2165

Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice.

D F Smee 1, S T Sugiyama 1, E J Reist 1
PMCID: PMC284702  PMID: 7811037

Abstract

Acyclovir phosphonate [9-(3-phosphono-propyloxymethyl)guanine; SR3722] and the S enantiomer (SR3772), R enantiomer (SR3773), and R,S enantiomeric mixture (SR3745A) of ganciclovir phosphonate (9-[((+/-)-1-hydroxymethyl-3-phosphono)propyloxymethyl]guanine) were evaluated for their antiviral activities against murine cytomegalovirus. In severe combined immunodeficient mice infected with murine cytomegalovirus, SR3773 and SR3745A (12.5, 25, and 50 mg/kg of body weight per day) were superior to ganciclovir in extending the mean time to death, whereas SR3722 and SR3772 was less potent than ganciclovir. In normal BALB/c mice, SR3773 and ganciclovir were approximately equally active in preventing death. SR3773 caused renal tubular damage when administered at 50 mg/kg/day for 15 days. These results suggest that SR3773 may have potential for use in the treatment of human cytomegalovirus infections, but it may also exhibit renal toxicity.

Full text

PDF
2165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnard D. L., Huffman J. H., Sidwell R. W., Reist E. J. Selective inhibition of cytomegaloviruses by 9-(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxy-methyl)g uanine. Antiviral Res. 1993 Sep;22(1):77–89. doi: 10.1016/0166-3542(93)90086-x. [DOI] [PubMed] [Google Scholar]
  2. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., Baumelou A., Dohin E., Gentilini M. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9(4):316–321. doi: 10.1159/000167987. [DOI] [PubMed] [Google Scholar]
  3. Duke A. E., Smee D. F., Chernow M., Boehme R., Matthews T. R. In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses. Antiviral Res. 1986 Aug;6(5):299–308. doi: 10.1016/0166-3542(86)90025-2. [DOI] [PubMed] [Google Scholar]
  4. Erice A., Chou S., Biron K. K., Stanat S. C., Balfour H. H., Jr, Jordan M. C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989 Feb 2;320(5):289–293. doi: 10.1056/NEJM198902023200505. [DOI] [PubMed] [Google Scholar]
  5. Leport C., Puget S., Pepin J. M., Levy S., Perronne C., Brun-Vezinet F., Vildé J. L. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis. 1993 Nov;168(5):1329–1330. doi: 10.1093/infdis/168.5.1329. [DOI] [PubMed] [Google Scholar]
  6. Neyts J., Balzarini J., Naesens L., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J Med Virol. 1992 May;37(1):67–71. doi: 10.1002/jmv.1890370112. [DOI] [PubMed] [Google Scholar]
  7. Neyts J., Sobis H., Snoeck R., Vandeputte M., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur J Clin Microbiol Infect Dis. 1993 Apr;12(4):269–279. doi: 10.1007/BF01967257. [DOI] [PubMed] [Google Scholar]
  8. Raju N., Smee D. F., Robins R. K., Vaghefi M. M. Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP. J Med Chem. 1989 Jun;32(6):1307–1313. doi: 10.1021/jm00126a027. [DOI] [PubMed] [Google Scholar]
  9. Sidwell R. W., Smee D. F., Warren R. P., Huffman J. H., Gilbert B. J., Burger R. A., Pearson F. C. Murine cytomegalovirus-inhibitory effects of ImuVert. Antiviral Res. 1993 Apr;20(4):279–292. doi: 10.1016/0166-3542(93)90072-q. [DOI] [PubMed] [Google Scholar]
  10. Smee D. F., Boehme R., Chernow M., Binko B. P., Matthews T. R. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol. 1985 Apr 1;34(7):1049–1056. doi: 10.1016/0006-2952(85)90608-2. [DOI] [PubMed] [Google Scholar]
  11. Smee D. F., Colletti A., Alaghamandan H. A., Allen L. B. Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus. Arch Virol. 1989;107(3-4):253–260. doi: 10.1007/BF01317921. [DOI] [PubMed] [Google Scholar]
  12. Smee D. F., Morris J. L., Leonhardt J. A., Mead J. R., Holy A., Sidwell R. W. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother. 1992 Sep;36(9):1837–1842. doi: 10.1128/aac.36.9.1837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Snoeck R., Sakuma T., De Clercq E., Rosenberg I., Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988 Dec;32(12):1839–1844. doi: 10.1128/aac.32.12.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES